Vertex Reports First Quarter 2015 Financial Results

Go back to Vertex Reports First Quarter 2015 Financial Results

Vertex (VRTX) Q1 Quiet, But Reimbursement Commentary 'Encouraging'; Leerink Says; PT Up to $150

April 30, 2015 6:18 AM EDT

Leerink Partners analyst Howard Liang reiterated an Outperform rating and boosted his price target on Vertex (NASDAQ: VRTX) to $150.00 (from $131.00) following a "quiet" quarter as reimbursement commentary was encouraging.

Liang commented, "VRTX reported roughly in-line Kalydeco sales for 1Q:15 ($130M vs. our/consensus estimates of $127M/$131M).... More

Vertex Pharma (VRTX) Tops Q1 EPS by 13c

April 29, 2015 4:03 PM EDT

Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of ($0.62), $0.13 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $138.5 million versus the consensus estimate of $142.38 million.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

... More